Начало・Списък с акции・Ocular Therapeutix Inc

Ocular Therapeutix Inc

Затворен

СекторЗдравеопазване

9.17 4.8

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.09

Максимум

9.18

Ключови измерители
By Trading Economics
Приходи	9.8M -79M
Продажби	2.7M 13M
EPS	-0.35
Марж на печалбата	-584.512
Служители	325
EBITDA	8.6M -76M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+180.52% upside

Дивиденти
By Acuity
Следващи печалби	3.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-47M 1.8B
Предишно отваряне	4.37
Предишно затваряне	9.17

Настроения в новините

By Acuity

34%

66%

75 / 340 Класиране в Healthcare

Ocular Therapeutix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.08.2026 г., 21:01 ч. UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

6.08.2026 г., 20:06 ч. UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

5.08.2026 г., 21:03 ч. UTC

Ocular Therapeutix Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains under pressure.

3.08.2026 г., 20:06 ч. UTC

Social Media

News

Ocular Therapeutix shares rise after reporting Q2 revenue of $13.5 million, exceeding estimates, and announcing plans for a new drug application for AXPAXLI.

31.07.2026 г., 21:01 ч. UTC

Ocular Therapeutix Inc shares are lower in after-market hours with no specific news identified. Broader market conditions reflect mixed performance amid rising inflation concerns.

30.07.2026 г., 19:39 ч. UTC

Ocular Therapeutix shares are higher today, continuing an upward trend since Wednesday. The U.S. Dollar Index decline may be influencing broader market dynamics.

28.07.2026 г., 19:06 ч. UTC

News

Ocular Therapeutix shares are lower amid broader market volatility and regulatory challenges, reaching a session low earlier today.

27.07.2026 г., 21:01 ч. UTC

Ocular Therapeutix Inc. shares are higher in after-market trading, reaching a peak shortly after the session began amid improved European market sentiment.

22.07.2026 г., 18:36 ч. UTC

Social Media

Ocular Therapeutix is presenting at the HC Wainwright conference, but shares are declining and remain below their 20-day moving average.

21.07.2026 г., 23:41 ч. UTC

Ocular Therapeutix Inc shares rose in after-market trading, reaching their highest cumulative return of the day. The stock remains below its 20-day moving average.

20.07.2026 г., 19:46 ч. UTC

Social Media

Ocular Therapeutix shares are lower today, continuing a downward trend. Early gains were followed by a pullback amid uncertain investor sentiment.

Сравнение с други в отрасъла

Ценова промяна

Ocular Therapeutix Inc Прогноза

Ценова цел

By TipRanks

180.52% нагоре

12-месечна прогноза

Среден 25.78 USD 180.52%

Висок 31 USD

Нисък 18 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocular Therapeutix Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Ocular Therapeutix Inc през последните 3 месеца.

Настроение

By Acuity

75 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.